Location: Newton, MA

Lumicell Appoints Felix Geissler, M.D., Ph.D. as Chief Medical Officer

Wellesley, Mass., June 28, 2017 – Lumicell, a leader in the field of image-guided cancer surgery, today announced the appointment of Felix Geissler, M.D., Ph.D. as Chief Medical Officer. As a central member of Lumicell’s senior executive team, he will drive the clinical direction of the company and will work closely with the R&D and marketing teams to develop the overall business strategy. Dr. Geissler previously held various roles within Sanofi Genzyme. Most recently, he was t...
Read More

Lumicell Awarded Direct Phase II Small Business Innovation Research (SBIR) Grant from the National Cancer Institute to Conduct Multi-Center Pivotal Study

Funding will Support Trial of the Lumicell Margin Assessment System (MAS) in Breast Cancer Surgery Wellesley, Mass., August 9, 2016 – Lumicell, a leader in the field of image-guided surgery, today announced that the National Cancer Institute (NCI) has awarded the Company a Phase II Small Business Innovation Research (SBIR) grant to fund a prospective multi-center pivotal study of the Lumicell Margin Assessment System (MAS) in breast cancer surgery. The company aims to demonstrate tha...
Read More

Lumicell Successfully Completes Phase 2a Feasibility Study

Revolutionary Approach to Imaging Tumor Cells Achieved 100% Detection of Residual Cancer and Well Tolerated in First Patient Samples Poster Presentation of Trial Findings at The American Society of Breast Surgeons Annual Meeting Wellesley, Mass., April 13, 2016 – Lumicell, a leader in the field of image-guided cancer surgery, today announced it successfully completed its Phase 2a feasibility study on the Company’s groundbreaking LUM Imaging System, consisting of an optical contrast...
Read More

Lumicell Publishes Data Supporting LUM015, Fluorescent Probe for Imaging Cancer, in Science Translational Medicine

Revolutionary Approach to Imaging Tumor Cells Demonstrated to be Well Tolerated in First Patient Samples Wellesley, Mass., January 6, 2016 – Lumicell, a leader in the field of image-guided cancer surgery, today announced the publication of research supporting the Company’s groundbreaking protease-activated fluorescent imaging probe, LUM015, in Science Translational Medicine. The research highlights the use of LUM015 to detect cancer in vivo in a mouse model of soft tissue...
Read More

Lumicell Announces FDA Approval to Launch Feasibility Study in Gastrointestinal Cancers

Trial is funded by National Cancer Institute’s SPORE program Wellesley, Mass., September 10, 2015 – Lumicell, a leader in the field of image-guided cancer surgery, has received approval from the U.S. Food and Drug Administration (FDA) to launch a feasibility (pilot) study in gastrointestinal cancers. The study will focus on imaging tissue in patients with esophageal, colorectal and pancreatic cancers. The study will be conducted at Massachusetts General Hospital (MGH) and will be led by...
Read More

Lumicell Announces FDA Approval to Launch Feasibility Study

Trial is funded by National Cancer Institute grant Wellesley, Mass., May 20, 2015 – Lumicell, a leader in the field of image-guided cancer surgery, has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to launch a feasibility (pilot) study for intraoperative imaging of breast cancer during surgery. The study will be conducted at Massachusetts General Hospital (MGH). Further trial information can be found here: https://clinicaltr...
Read More

Lumicell Phase 1 Results Presented at SSO 2015 Annual Cancer Symposium

Phase 1 Results Also Presented at AACR 2015 Annual Meeting Wellesley, Mass., May 8, 2015 – Lumicell, a leader in the field of image-guided cancer surgery, announced that Phase 1 trial results were recently presented at the SSO 2015 Annual Cancer Symposium in March and the AACR 2015 Annual Meeting in April. Both sessions were presented by Lumicell’s clinical collaborators at Duke University Medical Center. Lumicell recently completed its Phase 1 safety study at Duke University...
Read More

Lumicell Awarded SBIR Phase IIB Grant from National Science Foundation

Grant will support development of novel image-guided laser ablation system in collaboration with Massachusetts General Hospital, Brigham and Women’s Hospital and Duke University Medical Center Wellesley, Mass., May 14, 2014 – Lumicell, a leader in the field of image-guided cancer surgery, has received a Phase IIB Small Business Innovation Research (SBIR) grant from the National Science Foundation (NSF). The grant will support the company’s expansion into brain and ovarian cancer indic...
Read More

Lumicell Awarded SBIR Grant from the National Cancer Institute

Grant will support development of new imaging agents in collaboration with MIT, MGH and       Duke University Medical Center Wellesley, Mass., August 7, 2013 – Lumicell, a leader in the field of image-guided cancer surgery, has received a Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI). The grant will support the company’s pipeline expansion with the development of new imaging agents in collaboration with MIT, Massachusett...
Read More

Lumicell Awarded with an Accelerator Loan from the Massachusetts Life Sciences Center

Wellesley, Mass., May 29, 2013 – Lumicell announced it was awarded a $1 million accelerator loan from the Massachusetts Life Sciences Center (MLSC), a quasi-public agency charged with implementing the state’s 10-year, $1-billion Life Sciences Initiative. The MLSC’s Accelerator Loan Program provides loans of up to $1 million to early-stage companies engaged in life sciences research and development, commercialization and manufacturing. “This accelerator loan is of critical importance...
Read More
en_USEnglish